Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer

This study is ongoing, but not recruiting participants.

Study NCT00004931 Information provided by National Surgical Adjuvant Breast and Bowel Project (NSABP)

First Received: March 7, 2000 Last Updated: April 18, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	March 2012
Primary Completion Date:	September 2005 (Final data collection date for primary outcome measure)

Publications:

Wolmark N, Wieand S, Kuebler PJ, et al.: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: survival results of NSABP Protocol C-07. [Abstract] J Clin Oncol 26 (Suppl 15): A-LBA4005, 2008.

Philip Kuebler J, Colangelo L, O'connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer. 2007 Sep 12; [Epub ahead of print]

Kuebler JP, Wieand HS, O'connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07. J Clin Oncol. 2007 Apr 30; [Epub ahead of print]

Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'connell MJ, Costantino JP, Wolmark N. Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07. J Clin Oncol. 2007 Apr 30; [Epub ahead of print]

Land SR, Kopec J, Cecchini R, et al.: Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: results of NSABP Protocol C-07. [Abstract] J Clin Oncol 24 (Suppl 18): A-3564, 2006.

Wolmark N, Wieand HS, Kuebler JP, et al.: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C-07. [Abstract] J Clin Oncol 23 (Suppl 16): A-LBA3500, 246s, 2005.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW; ACCENT Collaborative Group. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011 Oct 19;103(20):1498-506. Epub 2011 Oct 12.

Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011 Oct 1;29(28):3768-74. Epub 2011 Aug 22.

Fumagalli D, Gavin PG, Taniyama Y, Kim SI, Choi HJ, Paik S, Pogue-Geile KL. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010 Mar 16;10:101.